MTA3 and melanoma: Similar studies by Lau et al. showed that PF543, a dual SK1/SK2 inhibitor with higher potency toward SK1 [82], enhanced the efficacy of anti-PD-1 antibodies against melanoma tumors, possibly by downregulation of MTA3 and c-Myc expression [83].